Autolus Therapeutics plc (NASDAQ:AUTL) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $9.52.

Several equities research analysts have recently commented on AUTL shares. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Wells Fargo & Company lowered their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.65 on Friday. The business’s fifty day moving average price is $1.97 and its two-hundred day moving average price is $2.85. The firm has a market capitalization of $439.06 million, a price-to-earnings ratio of -1.36 and a beta of 2.07. Autolus Therapeutics has a 52 week low of $1.56 and a 52 week high of $6.44.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AUTL. Virtus ETF Advisers LLC grew its holdings in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock worth $62,000 after purchasing an additional 6,081 shares during the period. Daiwa Securities Group Inc. boosted its stake in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock worth $56,000 after acquiring an additional 8,479 shares during the period. Bellevue Group AG boosted its position in Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares during the period. State Street Corp increased its holdings in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after purchasing an additional 10,401 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after purchasing an additional 10,866 shares during the period. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.